Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Mymetics Corp (MYMX)

Mymetics Corp (MYMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2
  • Shares Outstanding, K 152
  • Annual Sales, $ 1,080 K
  • Annual Income, $ -5,060 K
  • 60-Month Beta 1.97
  • Price/Sales 0.00
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MYMX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 11/20/23
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 unch
on 02/16/24
0.2605 -96.16%
on 01/25/24
-0.1200 (-92.31%)
since 01/04/24
3-Month
0.0100 unch
on 02/16/24
4.8000 -99.79%
on 11/30/23
-1.7900 (-99.44%)
since 11/14/23
52-Week
0.0100 unch
on 02/16/24
70.0000 -99.99%
on 03/08/23
-52.3900 (-99.98%)
since 02/16/23

Most Recent Stories

More News
Mymetics to Advance Preclinical Studies for Virosome-based COVID-19 Vaccine through Innosuisse Grant

- Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. - Mymetics, through its collaborator, the Department of Pneumology at the Inselspital, Bern...

MYMX : 0.0100 (-96.16%)
Mymetics Starts Second Preclinical Study for Virosome-based Covid-19 Vaccine

- Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform, evaluating different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based...

MYMX : 0.0100 (-96.16%)
Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine

- Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective...

MYMX : 0.0100 (-96.16%)
Mymetics Receives Support for Virosome-based Covid-19 Vaccine Development from European Vaccine Infrastructure Project (Transvac2)

EPALINGES, SWITZERLAND / ACCESSWIRE / June 11, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life...

MYMX : 0.0100 (-96.16%)
Mymetics Reports Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergy Immunotherapy

EPALINGES, SWITZERLAND / ACCESSWIRE / May 28, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life...

MYMX : 0.0100 (-96.16%)
Mymetics and Baylor College of Medicine start Research Collaboration for Virosome-based Covid-19 Vaccines

EPALINGES, SWITZERLAND / ACCESSWIRE / May 18, 2020 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life...

MYMX : 0.0100 (-96.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Mymetics main research efforts have been concentrated in the prevention and treatment of the AIDS virus. All of Mymetics activities have been conducted in Europe.

See More

Key Turning Points

3rd Resistance Point 0.0100
2nd Resistance Point 0.0100
1st Resistance Point 0.0100
Last Price 0.0100
1st Support Level 0.0100
2nd Support Level 0.0100
3rd Support Level 0.0100

See More

52-Week High 70.0000
Fibonacci 61.8% 43.2638
Fibonacci 50% 35.0050
Fibonacci 38.2% 26.7462
Last Price 0.0100
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar